The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Impact of implant depth on hydrodynamic function with the ALLEGRA transcatheter heart valve following valve-in-valve intervention

DOI: 10.4244/EIJ-D-19-00782

1. Center for Heart Valve Innovation, St Paul's Hospital, University of British Colombia, Vancouver, Canada, Canada
2. ViVitro Labs Inc, Victoria, Canada
3. New Valve Technology, Hechingen, Germany
4. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
5. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
6. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
7. Med. Klinik und Poliklinik II, Herzzentrum, Universitätsklinikum Bonn, Germany
8. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
9. Heart Center Lucerne, Luzerner Kantonsspital, Switzerland
10. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
11. Rigshospitalet, Cardiology, Copenhagen, Denmark
12. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
13. Centre for Heart Valve Innovation, St Paul’s Hospital, University of British Columbia, Vancouver, Canada
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

To read the full content of this article, please log in to download the PDF.

Aims: We assessed the impact of implant depth on hydrodynamic function following valve-in-valve (VIV) intervention using the ALLEGRA (New Valve Technology, Hechingen, Germany) transcatheter heart valve (THV) in three different surgical valve designs. 

Methods and results: Multiple implantation depths (+2mm, -2mm and -6mm) were tested using a 23mm ALLEGRA THV for VIV intervention in 19mm, 21mm, 23mm, and 25mm Epic, Mitroflow and Magna Ease bioprosthetic valves. Multimodality imaging and hydrodynamic evaluation was performed at each implantation depth. The 23mm ALLEGRA valve had gradients <20mmHg in the Mitroflow and Epic valves sized ³21mm, and in all sizes of the Magna Ease valve. Gradients did not increase significantly at lower implantation depths. The 19mm Epic (+2mm: 20.1±0.6mmHg, -2mm: 18.8±0.5mmHg, -6mm: 22.8±0.3mmHg) and 19mm Mitroflow (+2mm: 24.1±0.2mmHg, -2mm: 31.5±0.3mmHg, -6mm: 25.6±0.2mmHg) valves, had elevated mean gradients. In larger sized surgical valves (³23mm) the regurgitant fraction was higher at low implantation depths. Pinwheeling was significantly worse in the smaller sized (£21mm) surgical valves and also at low (<-2mm) implantation depth. 

Conclusions: The 23mm ALLEGRA valve had favourable (<20mmHg) gradients in all surgical valves sized ³21mm, even when the THV was implanted low. In 19mm sized Mitroflow and Epic valves, gradients were elevated (>20mmHg). While there was no major difference in mean transvalvular gradients, leaflet pinwheeling was worse at lower implantation depths.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?